Curingenetics LLC Granted United States Patent for JAK Inhibition as a Novel Therapy for Preventing Tumors in Peutz-Jeghers Syndrome

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Source:
    Global IP News (India), February 3, 2022 Pharmaceutical Patent News, 2pp
  • Additional Information
    • Abstract:
      Alexandria, Feb. 3 -- Curingenetics LLC has been granted a patent (11,234,983) for JAK inhibition as a novel therapy for preventing tumors in peutz-jeghers syndrome. This invention was developed by Ollila Saara, Makela Tomi and Moreno Eva Domenech. The patent application number is 16/443,386. The International Patent Classification codes are A61K 31/519 (20060101), A61P 35/00 (20060101) and A61K 9/00 (20060101)...